Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul DaSilva-Jardine is active.

Publication


Featured researches published by Paul DaSilva-Jardine.


Endocrinology | 1998

Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models.

Hua Zhu Ke; Vishwas M. Paralkar; William A. Grasser; D. Todd Crawford; Hong Qi; H.A. Simmons; C.M. Pirie; Kristin L. Chidsey-Frink; Thomas A. Owen; Steven L. Smock; Hong Ka Chen; Webster S. S. Jee; Kimberly O'keefe Cameron; Robert Louis Rosati; Thomas A. Brown; Paul DaSilva-Jardine; David Duane Thompson

We have discovered a new, nonsteroidal, potent estrogen agonist/antagonist, CP-336,156. CP-336,156 binds selectively and with high affinity to the human estrogen receptor-α with a half-inhibition concentration of 1.5 nm, which is similar to that seen with estradiol (4.8 nm). When given orally to immature (3-week-old) female Sprague-Dawley rats for 3 days at doses of 0.1, 1.0, 10, or 100 μg/kg·day, unlike 17α-ethynyl estradiol, CP-336,156 had no effect on uterine wet or dry weight. Similarly, no uterine hypertrophy was observed in aged (17-month-old) female rats treated (po) with CP-336,156 at 10 or 100 μg/kg·day for 28 days. We also found that CP-336,156 decreased total serum cholesterol and fat body mass and had no effect on lean body mass in these aged female rats. In 5-month-old ovariectomized (OVX) Sprague-Dawley female rats, CP-336,156 completely prevented OVX-induced increases in body weight gain, total serum cholesterol, and serum osteocalcin at doses between 10 and 1000 μg/kg·day after 4 weeks. At...


Journal of Medicinal Chemistry | 2012

Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn; Angel Guzman-Perez; John Litchfield; Robert J. Aiello; Judith L. Treadway; John C. Pettersen; Martha L. Minich; Kevin J. Filipski; Christopher S. Jones; Meihua Tu; Gary E. Aspnes; Hud Risley; Jianwei Bian; Benjamin D. Stevens; Patricia Bourassa; Theresa D’Aquila; Levenia Baker; Nicole Barucci; Alan Robertson; Francis Bourbonais; David R. Derksen; Margit MacDougall; Over Cabrera; Jing Chen; Amanda Lee Lapworth; James A. Landro; William J. Zavadoski; Karen Atkinson; Nahor Haddish-Berhane; Beijing Tan

Glucokinase is a key regulator of glucose homeostasis, and small molecule allosteric activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes. Systemically acting glucokinase activators (liver and pancreas) have been reported to be efficacious but in many cases present hypoglycaemia risk due to activation of the enzyme at low glucose levels in the pancreas, leading to inappropriately excessive insulin secretion. It was therefore postulated that a liver selective activator may offer effective glycemic control with reduced hypoglycemia risk. Herein, we report structure-activity studies on a carboxylic acid containing series of glucokinase activators with preferential activity in hepatocytes versus pancreatic β-cells. These activators were designed to have low passive permeability thereby minimizing distribution into extrahepatic tissues; concurrently, they were also optimized as substrates for active liver uptake via members of the organic anion transporting polypeptide (OATP) family. These studies lead to the identification of 19 as a potent glucokinase activator with a greater than 50-fold liver-to-pancreas ratio of tissue distribution in rodent and non-rodent species. In preclinical diabetic animals, 19 was found to robustly lower fasting and postprandial glucose with no hypoglycemia, leading to its selection as a clinical development candidate for treating type 2 diabetes.


Journal of Medicinal Chemistry | 2009

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.

David A. Griffith; John R. Hadcock; Shawn C. Black; Philip A. Iredale; Philip A. Carpino; Paul DaSilva-Jardine; Robert W. Day; Joseph DiBrino; Robert L. Dow; Margaret S. Landis; Rebecca E. O’Connor; Dennis O. Scott

We report the structure-activity relationships, design, and synthesis of the novel cannabinoid type 1 (CB1) receptor antagonist 3a (CP-945,598). Compound 3a showed subnanomolar potency at human CB1 receptors in binding (Ki = 0.7 nM) and functional assays (Ki = 0.12 nM). In vivo, compound 3a reversed cannabinoid agonist-mediated responses, reduced food intake, and increased energy expenditure and fat oxidation in rodents.


ACS Medicinal Chemistry Letters | 2011

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Robert L. Dow; Jian-Cheng Li; Michael P. Pence; E. Michael Gibbs; Jennifer L. LaPerle; John Litchfield; David W. Piotrowski; Michael John Munchhof; Tara B. Manion; William J. Zavadoski; Gregory S. Walker; R. Kirk McPherson; Susan Tapley; Eliot Sugarman; Angel Guzman-Perez; Paul DaSilva-Jardine

Acyl-CoA:diacylglycerol acyltransferase-1 (DGAT-1) catalyzes the final committed step in the biosynthesis of triglycerides. DGAT-1 knockout mice have been shown to be resistant to diet-induced obesity and have increased insulin sensitivity. Thus, inhibition of DGAT-1 may represent an attractive target for the treatment of obesity or type II diabetes. Herein, we report the discovery and characterization of a potent and selective DGAT-1 inhibitor PF-04620110 (3). Compound 3 inhibits DGAT-1 with an IC50 of 19 nM and shows high selectivity versus a broad panel of off-target pharmacologic end points. In vivo DGAT-1 inhibition has been demonstrated through reduction of plasma triglyceride levels in rodents at doses of ≥0.1 mg/kg following a lipid challenge. On the basis of this pharmacologic and pharmacokinetic profile, compound 3 has been advanced to human clinical studies.


Journal of Bone and Mineral Research | 2005

A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats.

Hua Zhu Ke; D. Todd Crawford; Hong Qi; H.A. Simmons; Thomas A. Owen; Vishwas M. Paralkar; Mei Li; Bihong Lu; William A. Grasser; Kimberly O'keefe Cameron; Bruce Allen Lefker; Paul DaSilva-Jardine; Dennis O. Scott; Qing Zhang; Xiao Yan Tian; Webster S. S. Jee; Thomas A. Brown; David Duane Thompson

CP432 is a newly discovered, nonprostanoid EP4 receptor selective prostaglandin E2 agonist. CP432 stimulates trabecular and cortical bone formation and restores bone mass and bone strength in aged ovariectomized rats with established osteopenia.


Journal of Medicinal Chemistry | 2009

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.

Robert L. Dow; Philip A. Carpino; John R. Hadcock; Shawn C. Black; Philip A. Iredale; Paul DaSilva-Jardine; Steven R. Schneider; Ernest S. Paight; David A. Griffith; Dennis O. Scott; Rebecca E. O’Connor; Chudy I. Nduaka

We report the design, synthesis, and structure-activity relationships of novel bicyclic lactam-based cannabinoid type 1 (CB(1)) receptor antagonists. Members of these series are potent, selective antagonists in in vitro/in vivo efficacy models of CB(1) antagonism and exhibit robust oral activity in rodent models of food intake. These efforts led to the identification of 19d, which has been advanced to human clinical trials for weight management.


MedChemComm | 2011

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn; Angel Guzman-Perez; Peter J. Oates; John Litchfield; Gary E. Aspnes; Arindrajit Basak; John William Benbow; Martin A. Berliner; Jianwei Bian; Chulho Choi; Kevin Daniel Freeman-Cook; Jeffrey W. Corbett; Mary Theresa Didiuk; Joshua R. Dunetz; Kevin J. Filipski; William M. Hungerford; Christopher S. Jones; Kapil Karki; Anthony Lai Ling; Jian-Cheng Li; Leena Patel; Christian Perreault; Hud Risley; James Saenz; Wei Song; Meihua Tu; Robert J. Aiello; Karen Atkinson; Nicole Barucci; David A. Beebe

Glucokinase is a key regulator of glucose homeostasis and small molecule activators of this enzyme represent a promising opportunity for the treatment of Type 2 diabetes. Several glucokinase activators have advanced to clinical studies and demonstrated promising efficacy; however, many of these early candidates also revealed hypoglycemia as a key risk. In an effort to mitigate this hypoglycemia risk while maintaining the promising efficacy of this mechanism, we have investigated a series of substituted 2-methylbenzofurans as “partial activators” of the glucokinase enzyme leading to the identification of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as an early development candidate.


Bioorganic & Medicinal Chemistry | 2003

Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs) : Discovery of capromorelin

Philip A. Carpino; Bruce Allen Lefker; Steven M. Toler; Lydia Codetta Pan; John R. Hadcock; Ewell R. Cook; Joseph DiBrino; Anthony Michael Campeta; Shari L. DeNinno; Kristin L. Chidsey-Frink; William A. Hada; John Inthavongsay; F.Michael Mangano; Michelle A. Mullins; David F. Nickerson; Oicheng Ng; C.M. Pirie; John A. Ragan; Colin R. Rose; David A. Tess; Ann S. Wright; Li Yu; Michael P. Zawistoski; Paul DaSilva-Jardine; Theresa C. Wilson; David Duane Thompson

Novel pyrazolinone-piperidine dipeptide derivatives were synthesized and evaluated as growth hormone secretagogues (GHSs). Two analogues, capromorelin (5, CP-424391-18, hGHS-R1a K(i)=7 nM, rat pituicyte EC(50)=3 nM) and the des-methyl analogue 5c (hGHS-R1a K(i)=17 nM, rat pituicyte EC(50)=3 nM), increased plasma GH levels in an anesthesized rat model, with ED(50) values less than 0.05 mg/kg iv. Capromorelin showed enhanced intestinal absorption in rodent models and exhibited superior pharmacokinetic properties, including high bioavailabilities in two animal species [F(rat)=65%, F(dog)=44%]. This short-duration GHS was orally active in canine models and was selected as a development candidate for the treatment of musculoskeletal frailty in elderly adults.


Bioorganic & Medicinal Chemistry Letters | 2002

Discovery and biological characterization of capromorelin analogues with extended half-lives

Philip A. Carpino; Bruce Allen Lefker; Steven M. Toler; Lydia Codetta Pan; John R. Hadcock; Marianne C. Murray; Ewell R. Cook; Joseph DiBrino; Shari L. DeNinno; Kristin L. Chidsey-Frink; William A. Hada; John Inthavongsay; Sharon K. Lewis; F.Michael Mangano; Michelle A. Mullins; David F. Nickerson; Oicheng Ng; C.M. Pirie; John A. Ragan; Colin R. Rose; David A. Tess; Ann S. Wright; Li Yu; Michael P. Zawistoski; John C. Pettersen; Paul DaSilva-Jardine; Theresa C. Wilson; David Duane Thompson

New tert-butyl, picolyl and fluorinated analogues of capromorelin (3), a short-acting growth hormone secretagogue (GHS), were prepared as part of a program to identify long-acting GHSs that increase 24-h plasma IGF-1 levels. Compounds 4c and 4d (ACD LogD values >or=2.9) displayed extended plasma elimination half-lives in dogs, primarily due to high volumes of distribution, but showed weak GH secretagogue activities in rats (ED(50)s>10 mg/kg). A less lipophilic derivative 4 (ACD LogD=1.6) exhibited a shorter canine half-life, but stimulated GH secretion in two animal species. Repeat oral dosing of 4 in dogs for 29 days (6 mg/kg) resulted in a significant down-regulation of the post dose GH response and a 60 and 40% increase in IGF-1 levels relative to pre-dose levels at the 8- and 24-h post dose time points. Compound 4 (CP-464709-18) has been selected as a development candidate for the treatment of frailty.


Bioorganic & Medicinal Chemistry Letters | 2003

Structure-activity relationship studies on 2-heteroaryl-4-arylimidazoles NPY5 receptor antagonists.

Richard L. Elliott; Robert M. Oliver; Janet A. LaFlamme; Melissa L. Gillaspy; Marlys Hammond; Richard F. Hank; Tristan S. Maurer; Demetria L. Baker; Paul DaSilva-Jardine; Ralph W. Stevenson; Christine M. Mack; James V. Cassella

A series of 2-heteroaryl-4-arylimidazoles with potent in vitro activity at the NPY5 receptor was developed. Introduction of electron-withdrawing groups on the 4-aryl ring led to a significant improvement of in vitro potency. Several analogues from this series had anorectic activity in rodent feeding models, but were also found to have undesired behavioral effects in spontaneous locomotor activity.

Researchain Logo
Decentralizing Knowledge